T2 Biosystems Inc. (TTOO)
T2 Biosystems Statistics
Share Statistics
T2 Biosystems has 28.05M shares outstanding. The number of shares has increased by 326.62% in one year.
| Shares Outstanding | 28.05M |
| Shares Change (YoY) | 326.62% |
| Shares Change (QoQ) | 20.38% |
| Owned by Institutions (%) | 2.34% |
| Shares Floating | 11.9M |
| Failed to Deliver (FTD) Shares | 2.56K |
| FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 834.76K, so 2.98% of the outstanding shares have been sold short.
| Short Interest | 834.76K |
| Short % of Shares Out | 2.98% |
| Short % of Float | 6.69% |
| Short Ratio (days to cover) | 1.26 |
Valuation Ratios
The PE ratio is -0.33 and the forward PE ratio is -0.2. T2 Biosystems's PEG ratio is 0.
| PE Ratio | -0.33 |
| Forward PE | -0.2 |
| PS Ratio | 2.28 |
| Forward PS | 0.1 |
| PB Ratio | -0.58 |
| P/FCF Ratio | -0.34 |
| PEG Ratio | 0 |
Enterprise Valuation
T2 Biosystems Inc. has an Enterprise Value (EV) of 50.2M.
| EV / Earnings | -1 |
| EV / Sales | 6.98 |
| EV / EBITDA | -1.14 |
| EV / EBIT | -1.01 |
| EV / FCF | -1.04 |
Financial Position
The company has a current ratio of 0.45, with a Debt / Equity ratio of -1.77.
| Current Ratio | 0.45 |
| Quick Ratio | 0.36 |
| Debt / Equity | -1.77 |
| Total Debt / Capitalization | 230.63 |
| Cash Flow / Debt | -0.97 |
| Interest Coverage | -9.3 |
Financial Efficiency
Return on equity (ROE) is 1.79% and return on capital (ROIC) is -231.4%.
| Return on Equity (ROE) | 1.79% |
| Return on Assets (ROA) | -1.44% |
| Return on Capital (ROIC) | -231.4% |
| Revenue Per Employee | $63,654.87 |
| Profits Per Employee | $-443,159.29 |
| Employee Count | 113 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 3.19 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -96% in the last 52 weeks. The beta is 0.33, so T2 Biosystems's price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | -96% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 44.31 |
| Average Volume (20 Days) | 1.29M |
Income Statement
In the last 12 months, T2 Biosystems had revenue of 7.19M and earned -50.08M in profits. Earnings per share was -19.19.
| Revenue | 7.19M |
| Gross Profit | -8.17M |
| Operating Income | -49.66M |
| Net Income | -50.08M |
| EBITDA | -43.88M |
| EBIT | -49.66M |
| Earnings Per Share (EPS) | -19.19 |
Balance Sheet
The company has 15.69M in cash and 49.5M in debt, giving a net cash position of -33.81M.
| Cash & Cash Equivalents | 15.69M |
| Total Debt | 49.5M |
| Net Cash | -33.81M |
| Retained Earnings | -584.3M |
| Total Assets | 18.08M |
| Working Capital | -14.65M |
Cash Flow
In the last 12 months, operating cash flow was -48.14M and capital expenditures -192K, giving a free cash flow of -48.33M.
| Operating Cash Flow | -48.14M |
| Capital Expenditures | -192K |
| Free Cash Flow | -48.33M |
| FCF Per Share | -18.52 |
Margins
Gross margin is -113.58%, with operating and profit margins of -690.45% and -696.19%.
| Gross Margin | -113.58% |
| Operating Margin | -690.45% |
| Pretax Margin | -696.19% |
| Profit Margin | -696.19% |
| EBITDA Margin | -609.97% |
| EBIT Margin | -690.45% |
| FCF Margin | -671.88% |
Dividends & Yields
TTOO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -15991.67% |
| FCF Yield | -1378.56% |
Analyst Forecast
The average price target for TTOO is $5, which is 4066.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 4066.7% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 13, 2023. It was a backward split with a ratio of 1:100.
| Last Split Date | Oct 13, 2023 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | -55.5 |
| Piotroski F-Score | 3 |